|
|
|
Volumn 23, Issue 1 SUPPL. 2, 1996, Pages 68-75
|
|
The role of taxanes in the treatment of breast cancer
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ANTIMETABOLITE;
ANTINEOPLASTIC AGENT;
CISPLATIN;
CREMOPHOR;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
PACLITAXEL;
TAXANE DERIVATIVE;
AREA UNDER THE CURVE;
BREAST CANCER;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DRUG EFFICACY;
DRUG FORMULATION;
EDEMA;
EFFUSION;
HUMAN;
MALE;
NEUTROPENIA;
PERIPHERAL NEUROPATHY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
SKIN TOXICITY;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
BRIDGED COMPOUNDS;
CLINICAL TRIALS, PHASE II;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG TOLERANCE;
FEMALE;
HUMANS;
PACLITAXEL;
PROSPECTIVE STUDIES;
RANDOMIZED CONTROLLED TRIALS;
REMISSION INDUCTION;
TAXOIDS;
|
|
EID: 0029865322
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (37)
|
|
References (0)
|
